Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Threshold Pharmaceuticals
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03098160CT.gov Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | — | Unknown | — | — | — |
NCT02402062CT.gov A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | — | Completed | — | — | — |
NCT01833546CT.gov A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | — | Completed | — | — | — |
NCT00743379CT.gov Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Evofosfamide (this asset) | Threshold Pharmaceuticals | P2 | B · 56 |
| Tinzaparin | Helsinki University Central Hospital | P4 | BBB |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Capecitabine | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Irinotecan | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| Desflurane | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | P4 | BB |
+42 more in the Pancreatic Neoplasm cohort
Other indications for Evofosfamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Adenocarcinoma | — | P3 | B · 63 |
| Neuroendocrine Neoplasm | — | P2 | CCC · 54 |
| Head And Neck Squamous Cell Carcinoma | — | P1/2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Evofosfamide in Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/evofosfamide-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →